Antiangiogenic Resistance: Novel Angiogenesis Axes Uncovered by Antiangiogenic Therapies Research
Gabriela Jiménez-Valerio, Oriol Casanovas1
1Tumor Angiogenesis Group, Catalan Institute of Oncology-IDIBELL, Av. Gran Via de l'Hospitalet 199- 203 (3rd floor), E-08908 L'Hospitalet de Llobregat, Barcelona, Spain.
Abstract:
The mechanisms of tumor growth and progression involve the activation of different processes such as neovascularization and angiogenesis. These processes involve tumoral cells and stromal cells. Hence, inhibiting angiogenesis affects tumor growth and proliferation in patients with different types of cancer. Nevertheless, tumoral cells and stromal components are responsible for the resistance to antiangiogenic therapies. The majority of tumors respond to this type of therapy; however, some tumors may be indifferent to antiangiogenic therapies (intrinsic resistance) and other tumors become resistant during treatment (acquired resistance). Different strategies have been proposed to prevent resistance. Preclinical studies and clinical trials are focused to fight this therapeutic approach in order to prevent or delay tumor resistance to antiangiogenic therapies.
Insights
Tumor growth relies on angiogenesis, but cancer cells can resist anti-angiogenic therapies. Strategies are being developed to overcome both intrinsic and acquired resistance to these treatments.
Area of Science:
- Oncology
- Cancer Biology
- Molecular Medicine
Background:
- Tumor growth and progression are complex processes involving neovascularization and angiogenesis.
- Angiogenesis, driven by tumoral and stromal cells, is crucial for tumor expansion and proliferation.
- Anti-angiogenic therapies target this process but face challenges due to tumor resistance.
Purpose of the Study:
- To explore the mechanisms of tumor resistance to anti-angiogenic therapies.
- To review strategies aimed at preventing or overcoming both intrinsic and acquired resistance.
- To highlight ongoing research and clinical trials focused on enhancing anti-angiogenic treatment efficacy.
Main Methods:
- Review of preclinical studies investigating resistance mechanisms.
- Analysis of clinical trial data on anti-angiogenic therapies.
- Examination of proposed strategies to combat tumor resistance.
Main Results:
- Tumoral and stromal cells contribute significantly to resistance against anti-angiogenic treatments.
- Tumors exhibit both intrinsic (pre-existing) and acquired (treatment-induced) resistance.
- A majority of tumors initially respond, but resistance remains a significant clinical challenge.
Conclusions:
- Overcoming resistance is critical for improving the effectiveness of anti-angiogenic therapies in cancer treatment.
- Developing novel strategies to prevent or delay resistance is an active area of research.
- Continued investigation through preclinical and clinical studies is essential to combat tumor resistance.
More Related Videos
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
15:40Forward Genetic Approach to Uncover Stress Resistance Genes in Mice — A High-throughput Screen in ES Cells
Published on: November 11, 2015
Related Concept Videos
Moments of Inertia for an Area about Inclined Axes
Mechanism of Angiogenesis
Angular Momentum and Principle Axes of Inertia
To put this equation into simpler terms, it can be reconfigured using rectangular coordinates. This involves choosing an alternative set of XYZ axes that are arbitrarily inclined with respect to the reference frame. The process of deriving the rectangular...
Relative Motion Analysis using Rotating Axes
However, to express the relative position of point B relative to point A, an additional frame of reference, denoted as x'y', is necessary. This additional frame not only translates but also rotates relative to the fixed frame, making it...
Relative Motion Analysis using Rotating Axes - Acceleration
Time differentiation is...
Resistivity
